Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Prescient TherapeuticsASX:PTX 3-Year EBITDA Growth Rate is 20.60% as of Jun. 2026, which is at its 10-year median of 20.60. The stock has 1 warning sign investors should review. Among 1,129 Biotechnology companies, Prescient Therapeutics ranks better than 57.13% on this metric.
During the past 3 years, the average EBITDA Per Share Growth Rate was 20.60% per year.
During the past 5 years, the average EBITDA Per Share Growth Rate was -5.50% per year.
During the past 10 years, the average EBITDA Per Share Growth Rate was 7.30% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
During the past 13 years, the highest 3-Year average EBITDA Per Share Growth Rate of Prescient Therapeutics was 70.20% per year. The lowest was -51.60% per year. And the median was 20.60% per year.
EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.
Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.
Prescient Therapeutics 3-Year EBITDA Growth Rate Related Terms
ASX:PTX vs VRTX, REGN, RVMD: 3-Year EBITDA Growth Rate Comparison
For the Biotechnology subindustry, Prescient Therapeutics's 3-Year EBITDA Growth Rate, along with its competitors' market caps and 3-Year EBITDA Growth Rate data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Prescient Therapeutics 3-Year EBITDA Growth Rate vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Prescient Therapeutics's 3-Year EBITDA Growth Rate distribution charts can be found below:
* The bar in red indicates where Prescient Therapeutics's 3-Year EBITDA Growth Rate falls into.
This is the 3-year average growth rate of EBITDA per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
What does a 3-Year EBITDA Growth Rate of 20.60% mean?
Prescient Therapeutics (ASX:PTX) has a 3-Year EBITDA Growth Rate of 20.60% as of Jun. 2026. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for Prescient Therapeutics and its competitors. This is near median its historical median of 20.60. According to the industry distribution chart, Prescient Therapeutics ranks #484 out of 1129 companies in the Biotechnology industry, placing it in the top 42.9%.
Is Prescient Therapeutics' 3-Year EBITDA Growth Rate too high?
Prescient Therapeutics' current 3-Year EBITDA Growth Rate of 20.60% is near median its 10-year median of 20.60. The Biotechnology industry median 3-Year EBITDA Growth Rate is 14.90. Prescient Therapeutics' value of 20.60% is 38.3% above this industry median. Based on the distribution chart, Prescient Therapeutics ranks #484 out of 1129 companies in the Biotechnology industry, which is above the industry midpoint.
How does Prescient Therapeutics' 3-Year EBITDA Growth Rate compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Prescient Therapeutics ranks #484 out of 1129 companies for 3-Year EBITDA Growth Rate. This puts Prescient Therapeutics in the upper half of its industry. The industry median 3-Year EBITDA Growth Rate is 14.90. Prescient Therapeutics' value of 20.60% is 38.3% above this benchmark. While the company's 10-year median is 20.60 vs. the industry median of 14.90, Prescient Therapeutics has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year EBITDA Growth Rate for a Biotechnology company?
The median 3-Year EBITDA Growth Rate among Biotechnology companies is 14.90, based on 1,129 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year EBITDA Growth Rate significantly above this median, while those in the bottom quartile fall well below. However, 3-Year EBITDA Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Prescient Therapeutics's current 3-Year EBITDA Growth Rate of 20.60% is 38.3% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year EBITDA Growth Rate mean?
A high 3-Year EBITDA Growth Rate can signal that a stock is expensive relative to its fundamentals. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for Prescient Therapeutics and its competitors. For the Biotechnology industry, the median 3-Year EBITDA Growth Rate is 14.90 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Prescient Therapeutics's current 3-Year EBITDA Growth Rate is 20.60%, which is near median its own 10-year median of 20.60. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Prescient Therapeutics stock overvalued right now?
Prescient Therapeutics (ASX:PTX) has a current 3-Year EBITDA Growth Rate of 20.60%. The current 3-Year EBITDA Growth Rate is 20.60%, which is near median its 10-year median of 20.60 and 38.3% above the Biotechnology industry median of 14.90. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year EBITDA Growth Rate calculated?
3-Year EBITDA Growth Rate is calculated from a company's financial statements. For Prescient Therapeutics (ASX:PTX), the current 3-Year EBITDA Growth Rate is 20.60% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Prescient Therapeutics Ltd is a clinical-stage oncology company. The company develops novel compounds for the treatment of a range of cancers in Australia. Its product in the pipeline includes OmniCAR; PTX-100 and PTX-200. OmniCAR is a universal immune receptor platform enabling controllable T-cell activity and multi-antigen targeting with a single cell product.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ASX:PTX has been successfully added to your 
